ArticleScientific reports2026
T cells assemble lentivirus to solve local delivery of stable gene therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent breakthroughs in cancer immunotherapy, solid tumors continue to evade treatment due to their immunosuppressive microenvironment. Gene therapy can make such “cold” tumors “hot”, initiate therapeutic chain reactions, repair cancer-specific genetic mutations, or solve cell pathologies; however, it lacks the specific delivery vehicle for tumors or genetic diseases. Here, I explore a T cell line as platform for lentiviral production and delivery. I show that Jurkat cells can produce functional lentivirus, successfully transferring a fluorescence reporter gene locally to cancer cells under controlled in vitro conditions and allowing quantification of efficiency. Furthermore, a Tet-On inducible promoter could precisely and timely regulate lentivirus production. The comprehensive lentiviral T cell system is anticipated to safely provide specific, efficient, and stable gene expression in vivo to any tissue in the future, with effortless adaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.